PacBio Q2 revenue up 10.5% YoY to $39.8M; GAAP net loss narrows to $41.9M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2025-Q2 EPS reported -$1.57 revenue$76,919,000

GAAP net loss per share of $0.14 improved from $0.64 YoY; non-GAAP EPS -$0.13 vs -$0.20.
Consumable revenue $18.9M (+11% YoY); service & other revenue $6.7M (+56% YoY).
Shipped 15 Revio and 38 Vega systems; Revio annualized pull-through ~$219K/system.
Cash, equivalents, and investments $314.7M, down from $509.8M a year earlier.
Non-GAAP operating expenses cut to $58.1M from $71.0M YoY; CEO cites disciplined cost management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.